A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
Ever since Type A personality was linked to cardiovascular disease in the 1950s, it’s been known that anger raises the risk of heart attack and stroke. Now a Columbia study may explain how.
Columbia neuroscientists found that the mouse brain can direct the body's immune system to an unexpected degree, a discovery that could lead to new therapies for many immune disorders.
A new study reveals how bone marrow stem cell niche generation is regulated, which could lead to improvements in stem cell transplantation for the treatment of blood diseases.
Arthur G. Palmer and Oliver Hobert of the Department of Biochemistry & Molecular Biophysics were selected in recognition of their distinguished and continuing achievements in research.
A study co-led by Columbia scientists suggests a nutrient transporter located at the blood-brain barrier could be commandeered to sneak therapeutic drugs into the brain.
Columbia researchers have found that cells inside clogged arteries have cancer-like properties that aggravate atherosclerosis, and anticancer drugs could be a new treatment.
Warning letters from Medicare sent to high prescribers reduced prescriptions of risky antipsychotics for elderly people with dementia without negatively affecting patient health.
People with a history of cognitively stimulating occupations during their 30s, 40s, 50s, and 60s had a lower risk of mild cognitive impairment and dementia after age 70.